Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Dragonfly Therapeutics
AstraZeneca
Exelixis
Mayo Clinic
Hoffmann-La Roche
Xencor, Inc.
Neonc Technologies, Inc.
ViroMissile, Inc.
Arcus Biosciences, Inc.
Bristol-Myers Squibb
Pfizer
Duke University
Tizona Therapeutics, Inc
Aulos Bioscience, Inc.
Novartis
Shanghai Henlius Biotech
OHSU Knight Cancer Institute
Wake Forest University Health Sciences
Poseida Therapeutics, Inc.
Werewolf Therapeutics, Inc.
MacroGenics
University of California, Davis
City of Hope Medical Center
ImmunityBio, Inc.
NRG Oncology
University of California, San Diego
Ocellaris Pharma, Inc.
Novartis
Bayer
City of Hope Medical Center
Kura Oncology, Inc.
Calico Life Sciences LLC
Mayo Clinic
GlaxoSmithKline
Bristol-Myers Squibb
Sairopa B.V.
Incyte Corporation
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
EMD Serono
Mayo Clinic
NeoTX Therapeutics Ltd.
LG Chem
HiFiBiO Therapeutics
HiFiBiO Therapeutics
Bolt Biotherapeutics, Inc.
Coherus Oncology, Inc.
University of Pittsburgh